Eliana Merle
Stock Analyst at Barclays
(3.74)
# 903
Out of 5,182 analysts
112
Total ratings
47.06%
Success rate
9.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Equal-Weight | $25 → $48 | $50.68 | -5.29% | 10 | Apr 2, 2026 | |
| INSM Insmed | Maintains: Overweight | $231 → $237 | $151.14 | +56.81% | 2 | Apr 1, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $24 → $41 | $40.84 | +0.39% | 10 | Apr 1, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $95 → $106 | $74.95 | +41.43% | 1 | Mar 26, 2026 | |
| QURE uniQure | Maintains: Equal-Weight | $31 → $25 | $17.92 | +39.51% | 6 | Mar 23, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Overweight | $923 | $746.46 | +23.65% | 1 | Mar 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $54.88 | +91.33% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $39.42 | +42.06% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.40 | -25.11% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $440.05 | +37.94% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $35.62 | +65.64% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $8 | $5.42 | +47.60% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $68 → $119 | $70.42 | +68.99% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $66 | $32.81 | +101.16% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $525.67 | +83.39% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.01 | +259.28% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $248.55 | +37.60% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.04 | +228.69% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $77.87 | +2.74% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $333.00 | +58.26% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.23 | +643.03% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $68.73 | -70.90% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $21.79 | -44.93% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $1.95 | +310.26% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $10.58 | +98.49% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $88.53 | -20.93% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $5.56 | -60.43% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $136.30 | -47.91% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $96.70 | +35.47% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $41.95 | -88.08% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $52.61 | -65.79% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.55 | +25.36% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $9.04 | +419.91% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.46 | +10.65% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $28.56 | +369.19% | 3 | Aug 19, 2020 |
Moderna
Apr 2, 2026
Maintains: Equal-Weight
Price Target: $25 → $48
Current: $50.68
Upside: -5.29%
Insmed
Apr 1, 2026
Maintains: Overweight
Price Target: $231 → $237
Current: $151.14
Upside: +56.81%
Apellis Pharmaceuticals
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $24 → $41
Current: $40.84
Upside: +0.39%
Ionis Pharmaceuticals
Mar 26, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $74.95
Upside: +41.43%
uniQure
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $17.92
Upside: +39.51%
Regeneron Pharmaceuticals
Mar 6, 2026
Initiates: Overweight
Price Target: $923
Current: $746.46
Upside: +23.65%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $54.88
Upside: +91.33%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $39.42
Upside: +42.06%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.40
Upside: -25.11%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $440.05
Upside: +37.94%
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $35.62
Upside: +65.64%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.42
Upside: +47.60%
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $70.42
Upside: +68.99%
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $32.81
Upside: +101.16%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $525.67
Upside: +83.39%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $5.01
Upside: +259.28%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $248.55
Upside: +37.60%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $10.04
Upside: +228.69%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $77.87
Upside: +2.74%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $333.00
Upside: +58.26%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.23
Upside: +643.03%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $68.73
Upside: -70.90%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $21.79
Upside: -44.93%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $1.95
Upside: +310.26%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $10.58
Upside: +98.49%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $88.53
Upside: -20.93%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $5.56
Upside: -60.43%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $136.30
Upside: -47.91%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $96.70
Upside: +35.47%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $41.95
Upside: -88.08%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $52.61
Upside: -65.79%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $17.55
Upside: +25.36%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $9.04
Upside: +419.91%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.46
Upside: +10.65%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $28.56
Upside: +369.19%